We are live on ! Find out more
AVAI

Atlas Venture Associates IX Portfolio holdings

AUM $11.8M
1-Year Est. Return 58.35%
This Fund
S&P 500
This Quarter Est. Return
+21.06%
1 Year Est. Return
-58.35%
3 Year Est. Return
-89.8%
5 Year Est. Return
-87.69%
10 Year Est. Return
–
AUM
$227M
AUM Growth
+$94.9M
Cap. Flow
+$61.2M
Cap. Flow %
26.92%
Top 10 Hldgs %
100%
Holding
7
New
2
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
SURF
Surface Oncology, Inc. Common Stock
SURF
+$67.2M
2
CBLK
Carbon Black, Inc. Common Stock
CBLK
+$4.67M

Top Sells

Rank Stock Value
1
NTLA icon
Intellia Therapeutics
NTLA
+$10.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.06%
2 Technology 2.07%
3 Communication Services 0.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SURF
1
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$75.8M 33.35%
+4,645,453
New +$67.2M
NTLA icon
2
Intellia Therapeutics
NTLA
$1.51B
$50.3M 22.12%
1,836,810
-442,978
-19% -$10.7M
COGT icon
3
Cogent Biosciences
COGT
$6.76B
$48.2M 21.23%
840,384
– –
SYBX
4
DELISTED
Synlogic
SYBX
$26.1M 11.47%
176,798
– –
SPRO icon
5
Spero Therapeutics
SPRO
$68.9M
$20.2M 8.89%
1,376,968
– –
CBLK
6
DELISTED
Carbon Black, Inc. Common Stock
CBLK
$4.71M 2.07%
+181,273
New +$4.67M
SNAP icon
7
Snap
SNAP
$7.96B
$1.97M 0.87%
150,160
– –

Similar funds

EEPIS
Evolution Equity Partners II SARL Luxembourg $11.8M AUM 63.6% 1-Year Est. Return
LM
Lockheed Martin Bethesda, Maryland $12.1M AUM 46.13% 1-Year Est. Return
HMP9
Highland Management Partners 9 Cambridge, Massachusetts $12.6M AUM 85.13% 1-Year Est. Return
TCSAM
Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return
AEM
ACON Equity Management Washington, District of Columbia $13.8M AUM 62.17% 1-Year Est. Return
PT
Palantir Technologies Denver, Colorado $9.72M AUM 6.46% 1-Year Est. Return
AR
Acacia Research New York $14.1M AUM 50.98% 1-Year Est. Return
MM
Malka Meyer $8.77M AUM 64.77% 1-Year Est. Return

Atlas Venture Associates IX's Q2 2018 Portfolio in Review

As of Q2 2018, Atlas Venture Associates IX held 7 positions worth $227M, up 72% from $132M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Atlas Venture Associates IX deployed $61.2M of net new capital in Q2 2018, opening 2 new positions. Its largest new stake was Surface Oncology, Inc. Common Stock: 4,645,453 shares worth $75.8M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Intellia Therapeutics, an estimated $10.7M trimmed.

  • Atlas Venture Associates IX's largest Q2 2018 buy was Surface Oncology, Inc. Common Stock: 4,645,453 shares worth $75.8M.
  • Atlas Venture Associates IX's biggest Q2 2018 reduction was Intellia Therapeutics, cutting an estimated $10.7M.
  • Atlas Venture Associates IX's ten largest holdings make up 100% of its $227M portfolio in Q2 2018.
  • Atlas Venture Associates IX opened 2 new positions and closed 0 in Q2 2018.
  • Atlas Venture Associates IX's portfolio value rose 72% quarter-over-quarter to $227M.

Based on Atlas Venture Associates IX's 13F filing for Q2 2018, filed 31 Jul 2018.